Ross Okimoto, M.D.
Clinical Instructor
Education
- Creighton University School of Medicine 2009
Residencies
- Tufts Medical Center, Internal Medicine 2012
Fellowships
- UCSF Medical Center, Medical Oncology 2014
Board Certifications
- American Board of Internal Medicine
- American Board of Internal Medicine, Medical Oncology
Clinical Expertise
- Bone Sarcoma
- Pulmonary Metastases
- Soft Tissue Sarcoma
Biography
Dr. Ross Okimoto is a medical oncologist specializing in the care of adult patients with soft tissue and bone sarcomas. He works with a team of surgeons, radiation oncologists and pathologists to provide the best possible outcomes for his patients.
Okimoto attended Creighton University School of Medicine. He completed his internal medicine residency training at Tufts Medical Center in Boston and his medical oncology fellowship at UCSF.
Awards & Honors
- NIH-NCI Career Development Award (K08), 2018-2023
- UCSF DOM Cohort Iniative Award, 2018
- A.P. Giannini Postdoctoral Fellowship, 2015
- Molecular Pathology NIH T32, 2014
Research Overview
A physician-scientist, Okimoto conducts research in addition to providing clinical care. The overall goal of his laboratory-based investigations is to help improve outcomes for cancer patients. His current research work focuses on understanding the molecular mechanisms that promote tumor cell metastasis.
Publications
Most recent publications from a total of 23
- , . Metastasis: From head to tail. Cell Cycle. 2017 Mar 19; 16(6):487-488. View in PubMed
- , Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, , Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, . Inactivation of Capicua drives cancer metastasis. Nat Genet. 2017 01; 49(1):87-96. View in PubMed
- , Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, . Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016 11 22; 113(47):13456-13461. View in PubMed
- Premasekharan G, Gilbert E, , Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, , Small EJ, , Collisson EA, Friedlander TW, Paris PL. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 09 28; 380(1):144-52. View in PubMed
- , . Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discov. 2016 Jan; 6(1):14-6. View in PubMed
- Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, , , Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, . RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. View in PubMed
- , . AXL receptor tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer (Auckl). 2015; 6:27-34. View in PubMed
- , Perry A, Rubenstein JL. 77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL). Brain Pathol. 2015 Jan; 25(1):111-2. View in PubMed
- , . Recent advances in personalized lung cancer medicine. Per Med. 2014; 11(3):309-321. View in PubMed
- , Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr Opin Hematol. 2011 Mar; 18(2):89-97. View in PubMed
- View All Publications